Journal of Thrombosis and Thrombolysis

, Volume 1, Issue 3, pp 237–249 | Cite as

Novel antithrombotic strategies for the treatment of coronary artery thrombosis: A critical appraisal

  • Paul R. Eisenberg
Article

Summary

Large-scale clinical trials have demonstrated that treatment of patients with acute myocardial infarction and unstable angina with antithrombotic agents significantly improves outcome. Despite the proven benefit of current therapies, there is a widespread perception that outcome could be enhanced further with novel antithrombotic agents. Enthusiasm for novel antithrombotic strategies has been stimulated by recent advances in the understanding of the mechanisms responsible for coronary artery thrombosis, which has led to the development of diverse inhibitors of platelet function and coagulation factors. In experimental models of coronary artery thrombosis, aspirin and heparin have been ineffective in preventing recurrent thrombosis after coronary thrombolysis and in preventing the progression of thrombosis in response to strong thrombogenic stimuli. In contrast, inhibitors of the platelet fibrinogen receptor, direct-acting thrombin inhibitors, and inhibitors of coagulation factors that promote elaboration of thrombin have been shown to be effective in attenuating arterial thrombosis in a variety of experimental preparations. Initial clinical trials with these agents have also documented efficacy in attenuating thrombotic events in patients treated with coronary thrombolysis and in those with unstable angina. However, optimal doses of novel antithrombotic agents, the degree to which combination antiplatelet and anticoagulant therapies are needed, and the risk/benefit ratio associated with specific novel antithrombotic drugs are still relatively undefined. With regard to the latter, it is possible that the large-scale clinical trials now in progress may show an increase in bleeding complications with novel anticoagulants compared with conventional therapy. Nonetheless, there are considerable data that suggest that treatment with aspirin and heparin is not completely effective in preventing the progression of thrombosis or its recurrence after interventions in high-risk subgroups of patients with coronary artery thrombosis and unstable coronary artery disease. Accordingly, continued investigation of a large variety of antithrombotic agents, both currently available and in development, should improve the treatment of highrisk patients with coronary disease if regimens with appropriate efficacy but without serious hemorrhagic effects can be designed.

Key words

anticoagulants myocardial infarction unstable angina coronary artery thrombosis antithrombins platelet inhibitors 
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    DeWood MA, Spores J, Notske RN, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction.N Engl J Med 1980;303:897–902.PubMedGoogle Scholar
  2. 2.
    Davies MJ, Thomas AC. Thromobosis and acute coronary artery lesions in sudden cardiac ischemic death.N Engl J Med 1984;310:1137–1140.PubMedGoogle Scholar
  3. 3.
    Ambrose JA, Winters SL, Stern A, et al. Angiographic morphology and the pathogenesis of unstable angina pectoris.J Am Coll Cardiol 1985;5:609–616.PubMedGoogle Scholar
  4. 4.
    Davies MJ, Thomas AC. Plaque fissuring-the cause of acute myocardial infarction, sudden ischemic death, and crescendo angina.Br Heart J 1985;53:363–373.PubMedGoogle Scholar
  5. 5.
    Falk E. Unstable angina with fatal outcome; dynamic coronary thrombosis leading to infarction and/or sudden death: Autopsy evidence of recurrent thrombosis with peripheral embolization culminating in total vascular occlusion.Circulation 1985;71:699–708.PubMedGoogle Scholar
  6. 6.
    Lewis HDJ, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: Results of a Veterans Administration cooperative study.N Engl J Med 1983;309: 396–403.PubMedGoogle Scholar
  7. 7.
    Cairns JA, Gent M, Singer J, et al. Aspirin, sulflnpyrazone, or both in unstable angina. Results of a Canadian multicenter trial.N Engl J Med 1985;313:1369–1375.PubMedGoogle Scholar
  8. 8.
    Gruppo Italiano per lo Studio della Streptochinasi nell'Infarcto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction.Lancet 1986;1:398–401.Google Scholar
  9. 9.
    ISIS-2 Study Group. ISIS-2 (Second International Study of Infarct Survival). Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected myocardial infarction: ISIS-2.Lancet 1988; 2:349.Google Scholar
  10. 10.
    Peto R, Gray R, Collins R, et al. Randomized trial of prophylactic daily aspirin in British male doctors.Br Med J 1988;296:313–316.Google Scholar
  11. 11.
    Hennekens CH, Buring JE, Sandercock P, Collins R, Peto R. Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease.Circulation 1989;80:749–756.PubMedGoogle Scholar
  12. 12.
    Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study.N Engl J Med 1989;321:129–135.Google Scholar
  13. 13.
    Aspirin Myocardial Infarction Study Group. A randomized, controlled trial of aspirin in persons recovering from myocardial infarction.JAMA 1980;243:661–669.Google Scholar
  14. 14.
    Persantine-Aspirin Reinfarction Study Group. Persantine and aspirin in coronary heart disease.Circulation 1980;62: 449–461.Google Scholar
  15. 15.
    Klimt CR, Knatterud GL, Stamler J, Meier P. Persantineaspirin reinfarction study. Part II. Secondary prevention with persantine and aspirin.J Am Coll Cardiol 1986;7: 251–269.PubMedGoogle Scholar
  16. 16.
    Antiplatelet Trialist's Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients.Br Med J 1994;308:81–106.Google Scholar
  17. 17.
    Thèroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina.N Engl J Med 1988; 319:1105–1111.PubMedGoogle Scholar
  18. 18.
    Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and rèinfarction after myocardial infarction.N Engl J Med 1990;323:147–152.PubMedGoogle Scholar
  19. 19.
    Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group. Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction.Lancet 1994;343:499–503.Google Scholar
  20. 20.
    Gold HK, Gimple LW, Yasuda T, Leinbach RC, Werner W, Holt R, Jordan R, Berger H, Collen D, Coller BS. Pharmacodynamic study of F(ab')2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein Ilb/IIIa in patients with unstable angina pectoris.J Clin Invest 1990;86:651–659.PubMedGoogle Scholar
  21. 21.
    Hanson SR, Harker LA. Interruption of acute plateletdependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone.Proc Natl Acad Sci USA 1988;85:3184–3188.PubMedGoogle Scholar
  22. 22.
    Haskel EJ, Adams SP, Feigen LP, et al. Prevention of reoccluding platelet-rich thrombi in canine femoral arteries with a novel peptide antagonist of platelet glycoprotein IIb/IIIa receptors.Circulation 1989;80:1775–1782.PubMedGoogle Scholar
  23. 23.
    Heras M, Chesebro JH, Penny WJ, Bailey KR, Badimon L, Fuster V. Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs. Heparin versus recombinant hirudin, a specific thrombin inhibitor.Circulation 1989;79:657~665.PubMedGoogle Scholar
  24. 24.
    Haskel EJ, Torr SR, Day KC, et al. Prevention of arterial reocclusion after thrombolysis with lipoprotein associated coagulation inhibitor (LACI).Circulation 1991;84:821–827.PubMedGoogle Scholar
  25. 25.
    Haskel EJ, Prager NA, Sobel BE, Abendschein DR. Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion.Circulation 1991;83:1048–1056.PubMedGoogle Scholar
  26. 26.
    Gold HK, Coller BS, Yasuda T, Saito T, Fallon JT, Guerrero JL, Leinbach RC, Ziskind, AA, Collen D. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation.Circulation 1988;77:670–677.PubMedGoogle Scholar
  27. 27.
    Eisenberg PR, Sherman LA, Schectman K, Perez J, Sobel BE, Jaffe AS. Fibrinopeptide A: A marker of acute coronary thrombosis.Circulation 1985;71:912–918.PubMedGoogle Scholar
  28. 28.
    Gallino A, Haeberli A, Baur HR, Straub PW. Fibrin formation and platelet aggregation in patients with severe coronary disease: Relationship with the degree of myocardial ischemia.Circulation 1985;72:27–30.PubMedGoogle Scholar
  29. 29.
    Hamsten A, Wiman B, de Faire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction.N Engl J Med 1985;313:1557–1563.PubMedGoogle Scholar
  30. 30.
    Eidt JF, Allison P, Noble S, et al. Thrombin is an important mediator of platelet aggregation in stenosed canine coronary arteries with endothelial injury.J Clin Invest 1989;84:18–27.PubMedGoogle Scholar
  31. 31.
    Munkvad S, Jespersen J, Gram J, Kluft C. Interrelationship between coagulant activity and tissue-type plasminogen activator (t-PA) system in acute ischaemic heart disease. Possible role of the endothelium.J Intern Med 1990:228:361–366.PubMedGoogle Scholar
  32. 32.
    Pearson PJ, Schaff HV, Vanhoutte PM. Acute impairment of endothelium-dependent relaxations to aggregating platelets following reperfusion injury in canine coronary arteries.Circ Res 1990;67:385–393.PubMedGoogle Scholar
  33. 33.
    Eisenberg PR, Kenzora JL, Sobel BE, Ludbrook PA, Jaffe AS. Relation between ST segment shifts during ischemia and thrombin activity in patients with unstable angina.J Am Coll Cardiol 1991;18:898.PubMedGoogle Scholar
  34. 34.
    Hawiger J. Adhesive interactions of platelets and their blockade.Ann NY Acad Sci 1991;614:270–278.PubMedGoogle Scholar
  35. 35.
    Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes.N Engl J Med 1992;326:310–318.PubMedGoogle Scholar
  36. 36.
    Gross GJ, O'Rourke ST, Pelc LR, Warltier DC. Myocardial and endothelial dysfunction after multiple, brief coronary occlusions: Role of oxygen radicals.Am J Physiol 1992;263: H1703-H1709.PubMedGoogle Scholar
  37. 37.
    Schneiderman J, Sawdey MS, Keeton MR, et al. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries.Proc Natl Acad Sci USA 1992;89:6998–7002.PubMedGoogle Scholar
  38. 38.
    Mazzone A, De Servi S, Ricevuti G, et al. Increased expression of neutrophil and monocyte adhesion molecules in unstable coronary artery disease.Circulation 1993;88:358–363.PubMedGoogle Scholar
  39. 39.
    Meng YY, Trachtenburg J, Ryan US, Abendschein DR. Potentiation of endogenous nitric oxide with Superoxide dismutase inhibits platelet-mediated thrombosis in injured and stenotic arteriesJ Am Coll Cardiol 1995;25:269–275.PubMedGoogle Scholar
  40. 40.
    Rentrop KP, Feit F, Blanke H, et al. Effects of intracoronary streptokinase and intracoronary nitroglycerine infusion on coronary angiographie patterns and mortality in patients with acute myocardial infarction.N Engl J Med 1984;311:1457–1463.PubMedGoogle Scholar
  41. 41.
    Heras M, Chesebro JH, Penny WJ, et al. The importance of adequate heparin dosage in arterial angioplasty in a porcine model.Circulation 1988;78:654–660.PubMedGoogle Scholar
  42. 42.
    Badimon L, Badimon JJ, Galvez A, Chesebro JH, Fuster V. Influence of arterial damage and wall shear rate on platelet deposition. Ex vivo study in a swine model.Arteriosclerosis 1986;6:312–320.PubMedGoogle Scholar
  43. 43.
    Weiss HJ, Turitto VT, Baumgartner HR. Role of shear rate and platelets in promoting fibrin formation on rabbit subendothelium. Studies utilizing patients with quantitative and qualitative defects.J Clin Invest 1986;78: 1072–1082.PubMedGoogle Scholar
  44. 44.
    Sakariassen KS, Fressinaud E, Girma JP, Meyer D, Baumgartner HR. Role of platelet membrane glycoproteins and von Willebrand factor in adhesion of platelets to subendothelium and collagen.Ann NY Acad Sci 1987;516: 52–65.PubMedGoogle Scholar
  45. 45.
    Sixma JJ, Nievelstein PF, Houdijk WP, Van BH, Hindriks G, de Groot PG. Adhesion of blood platelets to isolated components of the vessel wall.Ann NY Acad Sci 1987;509:103–117.PubMedGoogle Scholar
  46. 46.
    Badimon L, Badimon JJ, Turitto VT, Vallabhajosula S, Fuster V. Platelet thrombus formation on collagen type I. A model of deep vessel injury. Influence of blood rheology, von Willebrand factor, and blood coagulation.Circulation 1988;78:1431–1442.PubMedGoogle Scholar
  47. 47.
    Badimon L, Badimon JJ, Turitto VT, Fuster V. Role of von Willebrand factor in mediating platelet-vessel wall interaction at low shear rate; the importance of perfusion conditions.Blood 1989;73:961–967.PubMedGoogle Scholar
  48. 48.
    Sixma JJ, de Groot PG. Regulation of platelet adhesion to the vascular wall.Ann NY Acad Sci 1994;714:190–199.PubMedGoogle Scholar
  49. 49.
    Hawiger J. Formation and regulation of platelet and fibrin hemostatic plug.Human Pathol 1987;18:111.Google Scholar
  50. 50.
    Badimon L, Badimon JJ, Lassila R, Heras M, Chesebro JH, Fuster V. Thrombin regulation of platelet interaction with damaged vessel wall and isolated collagen type I at arterial flow conditions in a porcine model: Effects of hirudins, heparin and calcium chelation.Blood 1991;78: 423–434.PubMedGoogle Scholar
  51. 51.
    Lam JYT, Chesebro JH, Steele PM, et al. Antithrombotic therapy for deep arterial injury by angioplasty. Efficacy of common platelet inhibition compared with thrombin inhibition in pigs.Circulation 1991;84:814–820.PubMedGoogle Scholar
  52. 52.
    Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues.Am J Pathol 1989;134:1087–1097.PubMedGoogle Scholar
  53. 53.
    Weiss HJ, Turitto VT, Baumgartner HR, Nemerson Y, Hoffman T. Evidence for the presence of tissue factor activity on subendothelium.Blood 1989:73;968–975.PubMedGoogle Scholar
  54. 54.
    Bach RR. Initiation of coagulation by tissue factor.CRC Crit Rev Biochem 1988;23:339–367.PubMedGoogle Scholar
  55. 55.
    Mann KG, Nesheim ME, Church WR, Haley P, Krishnaswamy S. Surface-dependent reactions of the vitamin Independent enzyme complexes.Blood 1990;76:l-16.Google Scholar
  56. 56.
    Miletich JP, Jackson CM, Majerus PW. Properties of the factor Xa binding site on platelets.J Biol Chem 1978;253: 6908–6916.PubMedGoogle Scholar
  57. 57.
    Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque.Proc Nail Acad Sci USA 1989; 2839–2843.Google Scholar
  58. 58.
    Marmur JD, Rossikhina M, Guha A, Fyfe B, Friedrich V, Medlowitz M, Nemerson Y, Taubman MB. Tissue factor is rapidly induced in arterial smooth muscle after balloon injury.J Clin Invest 1993;91:2253–2259.PubMedGoogle Scholar
  59. 59.
    Hanson SR, Kotzke HF, Savage B, Harker LA. Platelet interactions with Dacron vascular grafts: A model of acute thrombosis in baboons.Arteriosclerosis. 1985;5:595–603.PubMedGoogle Scholar
  60. 60.
    GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction.N Engl J Med 1993;329:673–682.Google Scholar
  61. 61.
    EPIC Investigators. Prevention of ischemic complications in high-risk angioplasty by a chimeric monoclonal antibody c7E3 FAb fragment directed against the platelet glycoprotein IIb/IIIa receptor.N Engl J Med 1994;330:956–961.Google Scholar
  62. 62.
    Weiss HJ, Turitto VT, Baumgartner HR. Effect of shear rate on platelet interaction with subendothelium in citrated and native blood. I. Shear rate-dependent decrease of adhesion in von Willebrand's disease and Bernard-Soulier syndrome.J Lab Clin Med 1978;92:750–764.PubMedGoogle Scholar
  63. 63.
    Weiss HJ, Hawiger J, Ruggeri ZM, Turitto VT, Thiagarajan P, Hoffmann T. Fibrinogen-independent platelet adhesion and thrombus formation on subendothelium mediated by glycoprotein IIb-IIIa complex at high shear rate.J Clin Invest 1989;83:288–297.PubMedGoogle Scholar
  64. 64.
    Prager NA, Torr-Brown SR, Sobel BE, Abendschein DR. Maintenance of patency after thrombolysis in stenotic coronary arteries requires combined inhibition of thrombin and platelets.J Am Coll Cardiol 1993;22:296–301.PubMedGoogle Scholar
  65. 65.
    Wilner GD, Danitz MP, Mudd MS, Hsieh K, Fenton JW. Selective immobilization of alpha-thrombin by surfacebound fibrin.J Lab Clin Med 1981;97:403–411.PubMedGoogle Scholar
  66. 66.
    Hogg PJ, Jackson CM. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: Implications for heparin efficacy.Proc Natl Acad Sci USA 1989;86: 3619–3623.PubMedGoogle Scholar
  67. 67.
    Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.J Clin Invest 1990;86:385–391.PubMedGoogle Scholar
  68. 68.
    Eitzman DT, Chi L, Saggin L, Schwartz RS, Lucchesi BR, Fay WP. Heparin neutralization by platelet-rich thrombi. Role of platelet factor 4.Circulation 1994;89:1523–1529.PubMedGoogle Scholar
  69. 69.
    Teitel JM, Rosenberg RD. Protection of factor Xa from neutralization by heparin-antithrombin complex.J Clin Invest 1983;71:1383–1391.PubMedGoogle Scholar
  70. 70.
    Eisenberg PR, Siegel JE, Abendschein DR, Miletich JP. Importance of factor Xa in determining the procoagulant activity of whole-blood clots.J Clin Invest 1993;91:1877–1883.PubMedGoogle Scholar
  71. 71.
    Vlasuk G, Sitko G, Shebuski R. Specific factor Xa inhibition enhances thrombolytic reperfusion and prevents acute reocclusion in the canine copper coil model of arterial thrombosis.Circulation 1990;82(suppl III):III-603.Google Scholar
  72. 72.
    Sitko GR, Ramjit DR, Stabilito II, Lehman D, Lynch JJ, Vlasuk GP. Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide.Circulation 1992;85:805–815.PubMedGoogle Scholar
  73. 73.
    Gruber A, Griffin JH, Harker LA, Hanson SR. Inhibition of platelet-dependent thrombus formation by human activated protein C in a primate model.Blood 1989;73:639–642.PubMedGoogle Scholar
  74. 74.
    Gruber A, Hanson SR, Kelly AB, Yan BS, Bang N, Griffin JH, Harker L. Inhibition of thrombus formation by activated recombinant protein C in a primate model of arterial thrombosis.Circulation 1990;82:578–585.PubMedGoogle Scholar
  75. 75.
    Sakamoto T, Ogawa H, Yasue H, Oda Y, Kitajima S, Tsumoto K, Mizokami H. Prevention of arterial reocclusion after thrombolysis with activated protein C. Comparison with heparin in a canine model of coronary artery thrombosis.Circulation 1994;90:427–432.PubMedGoogle Scholar
  76. 76.
    Nicolini FA, Lee P, Rios G, Kottke-Marchant K, Topol EJ. Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis.Circulation 1994;89:1802–1809.PubMedGoogle Scholar
  77. 77.
    Abendschein D, Torr-Brown S, Meng YY, Wun TC, Sobel BE. Prevention of coronary arterial reocclusion after thrombolysis with recombinant tissue-factor pathway inhibitor.Circulation 1993;88(suppl I):I-417.Google Scholar
  78. 78.
    Coller BS, Scudder LE, Berger HJ, Iuliucci JD. Inhibition of human platelet function in vivo with a monoclonal antibody. With observations on the newly dead as experimental subjects.Ann Intern Med 1988;109:635–638.PubMedGoogle Scholar
  79. 79.
    Coller BS, Folts JD, Smith SR, Scudder LE, Jordan R. Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet GPIIb/ IIIa receptor. Correlation with bleeding time, platelet aggregation, and blockade of GPIIb/IIIa receptors.Circulation 1989;80:1766–1774.PubMedGoogle Scholar
  80. 80.
    Sherman CT, Litvack F, Grundfest W, et al. Coronary angioscopy in patients with unstable angina pectoris.N Engl J Med 1986;315:913–919.PubMedGoogle Scholar
  81. 81.
    Johnsson H, Oe, Paul C. Fibrinopeptide A (FPA) in patients with acute myocardial infarction.Thromb Res. 1979; 16:255–260.PubMedGoogle Scholar
  82. 82.
    Neri Serneri GG, Gg, Abbate R, Mugnaini C, Favilla S, Brunelli C, Chiercha S, Parodi O. Increased fibrinopeptide A formation and thromboxane A2 production in patients with ischemic heart disease: Relationships to coronary pathoanatomy, risk factors, and clinical manifestations.Am Heart J 1981;101:185–194.PubMedGoogle Scholar
  83. 83.
    Mombelli G, Im Hof V, Haeberli A, Straub PW. Effect of heparin on plasma fibrinopeptide A in patients with acute myocardial infarction.Circulation 1984;69:684–689.PubMedGoogle Scholar
  84. 84.
    Thèroux P, Latour J, Lèger-Gauthier C, De Lara J. Fibrinopeptide A and platelet factor levels in unstable angina pectoris.Circulation 1987;75:156–162.PubMedGoogle Scholar
  85. 85.
    Neri Serneri GG, Abbate R, Prisco D, Carnovali M, Fazi A, Casolo GC, Bonechi F, Rogasi PG, Gensini GF. Decrease in frequency of anginal episodes by control of thrombin generation with low-dose heparin: A controlled cross-over randomized study.Am Heart J 1988;115:60–67.PubMedGoogle Scholar
  86. 86.
    Wilensky RL, Zj, Wish M, Tulchinsky M. Urinary fibrinopeptide A levels in ischemic heart disease.J Am Coll Cardiol 1989;14:597–603.PubMedGoogle Scholar
  87. 87.
    Merlini PA, Bauer KA, Oltrona L, Ardissino D, Cattaneo M, Belli C, Mannucci PM, Rosenberg RD. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction.Circulation 1994;90:61–68.PubMedGoogle Scholar
  88. 88.
    Nossel HL, Yudelman RE, Canfleld VP, et al. Measurement of fibrinopeptide A in human blood.J Clin Invest 1974;54:43–53.PubMedGoogle Scholar
  89. 89.
    Eisenberg PR, Sherman LA, Rich M, et al. Importance of continued activation of thrombin reflected by flbrinopeptide A to the efficacy of thrombolysis.J Arn Coll Cardiol 1986;7:1255–1262.Google Scholar
  90. 90.
    Eisenberg PR, Sherman LA, Jaffe AS. Paradoxic elevation of flbrinopeptide A: Evidence for continued thrombosis despite intensive fibrinolysis.J Am Coll Cardiol 1987;10: 527–529.PubMedGoogle Scholar
  91. 91.
    Rapold HJ, Weiss M, Baur H, Haeberli A. Monitoring of fibrin generation during thrombolytic therapy of acute myocardial infarction with recombinant tissue-type plasminogen activator.Circulation 1989;79:980–989.PubMedGoogle Scholar
  92. 92.
    Rapold HJ. Promotion of thrombin activity by thrombolytic therapy without simultaneous anticoagulation.Lancet 1990;1:481–482.Google Scholar
  93. 93.
    Rapold HJ, de Bono D, Arnold AER, Arnout J, De Cock F, Collen D, Verstraete M. Plasma fibrinopeptide A levels in patients with acute myocardial infarction treated with alteplase.Circulation 1992;85:928–934.PubMedGoogle Scholar
  94. 94.
    Eisenberg PR, Sobel BE, Jaffe AS. Activation of prothrombin accompanying thrombolysis with rt-PA.J Am Coll Cardiol 1992;19:1065–1069.PubMedGoogle Scholar
  95. 95.
    Gulba DC, Westhoff-Bleck M, Jost S, et al. Increased thrombin levels during thrombolytic therapy in acute myocardial infarction.Circulation 1991;83:937–944.PubMedGoogle Scholar
  96. 96.
    Tripoldi A, Chantarngkul V, Bottasso B, Mannucci PM. Poor comparibility of prothrombin fragment 1 + 2 values measured by two commercial ELISA methods: Influence of different anticoagulants and standards.Thromb Haemost 1994;71:605–608.PubMedGoogle Scholar
  97. 97.
    Woodhams BJ, Kernoff PBA. Problems with antisera specificity in immunoassays for human fibrinopeptide A.Thromb Res 1986;42:689–693.PubMedGoogle Scholar
  98. 98.
    Nichols AB, Owen J, Grossman BA, Marcella JJ, Fleisher LN, Lee MML. Effect of heparin bonding on catheterinduced fibrin formation and platelet activation.Circulation 1984;70:843–850.PubMedGoogle Scholar
  99. 99.
    Wilner GD, Chatpar P, Arnanda T, Horowitz J. Effects of extravascular clotting on fibrinopeptide A levels in blood.J Lab Clin Med 1978;91:205–213.PubMedGoogle Scholar
  100. 100.
    Weitz JI, Cruickshank MK, Thong B, et al. Human tissuetype plasminogen activator releases fibrinopeptides A and B from flbrinogen.J Clin Invest 1988;82:1700–1707.PubMedGoogle Scholar
  101. 101.
    Eisenberg PR, Miletich JP. Proteolysis of prothrombin with pharmacologic plasminogen activation (abstract).Circulation 1989;80(suppl II):II-317.Google Scholar
  102. 102.
    Rogers WJ, Baim DS, Gore JM, et al. Comparison of immediate invasive, delayed invasive, and conservative strategies after tissue-type plasminogen acivator. Results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II-A trial.Circulation 1990;81:1707–9.PubMedGoogle Scholar
  103. 103.
    The TIMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial.N Engl J Med 1989;320:618–627.Google Scholar
  104. 104.
    Global Use of Strategies to Open Occluded Arteries (GUSTO) Ha Investigators. Randomized trial of intravenous heparin verus recombinant hirudin for acute coronary syndromes.Circulation 1994;90:1631–1637.Google Scholar
  105. 105.
    Fitzgerald DJ, Catella F, Roy L, FitzGerald GA. Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction.Circulation 1988;77:142–150.PubMedGoogle Scholar
  106. 106.
    Fitzgerald DJ, Wright F, FitzGerald GA. Increased thromboxane biosynthesis during coronary thrombolysis. Evidence that platelet activation and thromboxane A2 modulate the response to tissue-type plasminogen activator in vivo.Circ Res 1989;65:83–94.PubMedGoogle Scholar
  107. 107.
    Bleich SD, Schumacher RR, Cooke DH, Tate DA, Teichman SL. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarctionAra J Cardiol 1990;66: 1412–1417.Google Scholar
  108. 108.
    Hsia J, Hamilton WP, Kleiman NS, Roberts R, Chaitman BR, Ross AM. A comparison between heparin and lowdose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction.N Engl J Med 1990;323:1433–1437.PubMedGoogle Scholar
  109. 109.
    de Bono DP, Simoons ML, Tijssen J, et al. Early intravenous heparin improves coronary patency in thrombolysis with recombinant tissue-type plasminogen activator.Br Heart J 1992;67:122–128.PubMedGoogle Scholar
  110. 110.
    Coller BS, Scudder LE. Inhibition of dog platelet function by in vivo infusion of F(ab')2 fragments of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor.Blood 1985;66:1456–1459.PubMedGoogle Scholar
  111. 111.
    Coller BS, Folts JD, Scudder LE, Smith SR. Antithrombotic effect of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor in an experimental animal model.Blood 1986;68:783–786.PubMedGoogle Scholar
  112. 112.
    Mickelson JK, Simpson PJ, Gallas MT, Lucchesi BR. Thromboxane biosynthesis inhibition with CGS 13080 improves coronary blood flow after streptokinase-induced thrombolysis.Am Heart J 1987;113:1345–1352.PubMedGoogle Scholar
  113. 113.
    Golino P, Ashton JH, Glas-Greenwalt P, McNatt J, Buja LM, Willerson JT. Mediation of reocclusion by thromboxane A2 and serotonin after thrombolysis with tissue-type plasminogen activator in a canine preparation of coronary thrombosis.Circulation 1988;77:678–684.PubMedGoogle Scholar
  114. 114.
    Huang TF, Holt JC, Kirby EP, Niewiarowski S. Trigramin: Primary structure and its inhibition of von Willebrand factor binding to glycoprotein IIb/IIIa complex on human platelets.Biochemistry 1989;28:661–666.PubMedGoogle Scholar
  115. 115.
    Coller B. Platelets and thrombolytic therapy.N Engl J Med 1990;332:33–42.Google Scholar
  116. 116.
    Nicholson NS, Panzer KSG, Salyers AK, et al. Antiplatelet and antithrombotic effects of platelet glycoprotein IIb/IIIa (GPIIb/IIIa) inhibition by arginine-glycine-aspartic acidserine (RGDS) and arginine-glycine-aspartic acid (RGD) (O-me)Y (SC-46749)J Pharm Exp Ther 1991;256:876–882.Google Scholar
  117. 117.
    Simpson PJ, Schiern JA, Jakubowski JA, Smallwood JK. The role of serotonin (5HT2) receptor blockade in myocardial reperfusion injury: Effects of LY53857 in a canine model of myocardial infarction.J Pharm Exp Therap 1991; 258:979–985.Google Scholar
  118. 118.
    Rubin BG, McGraw DJ, Sicard GA, Santoro SA. New RGD analogue inhibits human platelet adhesion and aggregation and eliminates platelet deposition on canine vascular grafts.J Vasc Surg 1992;15:683–691.PubMedGoogle Scholar
  119. 119.
    Kleiman NS, Ohman EM, Califf RM, et al. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 pilot study.J Am Coll Cardiol 1993;22:381–389.PubMedGoogle Scholar
  120. 120.
    Topol EJ, Califf RM, Weisman HF, et al. Randomized trial of coronary intervetion with antibody against platelet lIb/ IIIa integrin for reduction of clinical restenosis: Results at six months.Lancet 1994;343:881–886PubMedGoogle Scholar
  121. 121.
    RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease.Lancet 1990;336:827–830.Google Scholar
  122. 122.
    Holdwright D, Patel D, Cunningham D, et al. Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina.J Arn Coll Cardiol 1994;24: 39–45.Google Scholar
  123. 123.
    Cruickshank MK, Levine MN, Hirsh J, Roberts R, Siguenza M. A standardized heparin nomogram for the management of heparin therapy.Arch Intern Med 1991;151: 333–337.PubMedGoogle Scholar
  124. 124.
    Fenton JW, Ni F, Witting JI, Brezniak DV, Andersen TT, Malik AB. The rational design of thrombin-directed antithrombotics.Adv Exp Med Biol 1993;340:1–13.PubMedGoogle Scholar
  125. 125.
    Maraganore JM. Thrombin, thrombin inhibitors, and the arterial thrombotic process.Thromb Haemost 1993;70:208–211.PubMedGoogle Scholar
  126. 126.
    Markwardt F, Hauptmann J. Synthetic thrombin inhibitors as anticoagulants pharmacological aspects [review].Adv Exp Med Biol 1993;340:143–171.PubMedGoogle Scholar
  127. 127.
    Okamoto S, Wanaka K, Hijikata-Okunomiya A. In vitro and in vivo properties of synthetic inhibitors of thrombin: recent advances.Adv Exp Med Biol 1993;340;119–130.PubMedGoogle Scholar
  128. 128.
    Harker LA. Strategies for inhibiting the effects of thrombin.Blood Coagul Fibrinolysis 1994;5:S59-S64.Google Scholar
  129. 129.
    Maraganore JM, Chao B, Joseph ML, Jablonski J. Anticoagulant activity of synthetic hirudin peptides.J Biol Chem 1989;264:8692–8698.PubMedGoogle Scholar
  130. 130.
    Maraganore JM, Fenton JWd. Thrombin inhibition by synthetic hirudin peptides.Adv Exp Med Biol 1990;281: 177–183.PubMedGoogle Scholar
  131. 131.
    Naski MC, Fenton JWd, Maraganore JM, Olson ST, Shafer JA. The COOH-terminal domain of hirudin. The exositedirected competitive inhibitor of the action of alpha-thrombin on fibrinogen.J Biol Chem 1990;265:13484–13489.PubMedGoogle Scholar
  132. 132.
    Fenton JW, Villanueva GB, Ofosu FA, Maraganore JM. Thrombin inhibition by hirudin: how hirudin inhibits thrombin.Haemostasis. 1991;1:27–31.Google Scholar
  133. 133.
    Cannon CP, McCabe CH, Henry TD, et al. Hirudin reduces reocclusion compared to heparin following thrombolysis in acute myocardial infarction: Results of the TIMI 5 trial.J Am Coll Cardiol 1993;21:136A.Google Scholar
  134. 134.
    Antman EM. Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial.Circulation. 1994;90:1624–30.PubMedGoogle Scholar
  135. 135.
    Lidon RM, Theroux P, Juneau M, Adelman B, Maraganore J. Initial experience with a direct antithrombin, Hirulog, in unstable angina. Anticoagulant, antithrombotic, and clinical effects.Circulation 1993;88:1495–1501.PubMedGoogle Scholar
  136. 136.
    Broze GJJ, Warren LA, Novotny WF, Higuchi DA, Girard JJ, Miletich JP. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action.Blood 1988;71;335–343.PubMedGoogle Scholar
  137. 137.
    Benedict CR, Ryan J, Wolitzky B, Ramos R, Gerlach M, Tijburg P, Stern D. Active site-blocked factor IXa prevents intravascular thrombus formation in the coronary vasculature without inhibiting extravascular coagulation in a canine thrombosis model.J Clin Invest 1991;88:1760–1765.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1995

Authors and Affiliations

  • Paul R. Eisenberg
    • 1
  1. 1.Cardiovascular DivisionWashington University School of MedicineSt. Louis

Personalised recommendations